Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Update on phase III LEAP-001 trial evaluating Keytruda (pembrolizumab) + Lenvima (lenvatinib) as first-line treatment for advanced or recurrent endometrial carcinoma – Merck Inc + Eisai

Written by | 13 Dec 2023

Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.